Sign In
Buy SAIC
SCIENCE APPLICATIONS INTERNATIONAL Earnings Calls
| Release date | Jun 01, 2026 |
| EPS estimate | $2.28 |
| EPS actual | $3.23 |
| EPS Surprise | 41.67% |
| Revenue estimate | 1.822B |
| Revenue actual | 1.906B |
| Revenue Surprise | 4.59% |
| Release date | Mar 16, 2026 |
| EPS estimate | $2.31 |
| EPS actual | $2.62 |
| EPS Surprise | 13.42% |
| Revenue estimate | 1.752B |
| Revenue actual | 1.75B |
| Revenue Surprise | -0.0958% |
| Release date | Dec 04, 2025 |
| EPS estimate | $2.07 |
| EPS actual | $2.58 |
| EPS Surprise | 24.64% |
| Revenue estimate | 1.868B |
| Revenue actual | 1.866B |
| Revenue Surprise | -0.101% |
| Release date | Sep 04, 2025 |
| EPS estimate | - |
| EPS actual | $2.71 |
| Revenue estimate | - |
| Revenue actual | 1.769B |
Last 4 Quarters for SCIENCE APPLICATIONS INTERNATIONAL
Below you can see how SAIC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Sep 04, 2025 |
| Price on release | $106.22 |
| EPS estimate | - |
| EPS actual | $2.71 |
| Date | Price |
|---|---|
| Aug 28, 2025 | $117.84 |
| Aug 29, 2025 | $117.70 |
| Sep 02, 2025 | $118.27 |
| Sep 03, 2025 | $114.11 |
| Sep 04, 2025 | $106.22 |
| Sep 05, 2025 | $104.93 |
| Sep 08, 2025 | $102.60 |
| Sep 09, 2025 | $102.78 |
| Sep 10, 2025 | $103.11 |
| 4 days before | -9.86% |
| 4 days after | -2.93% |
| On release day | -1.21% |
| Change in period | -12.50% |
| Release date | Dec 04, 2025 |
| Price on release | $101.79 |
| EPS estimate | $2.07 |
| EPS actual | $2.58 |
| EPS surprise | 24.64% |
| Date | Price |
|---|---|
| Nov 28, 2025 | $86.21 |
| Dec 01, 2025 | $86.24 |
| Dec 02, 2025 | $87.56 |
| Dec 03, 2025 | $87.53 |
| Dec 04, 2025 | $101.79 |
| Dec 05, 2025 | $100.61 |
| Dec 08, 2025 | $98.93 |
| Dec 09, 2025 | $97.32 |
| Dec 10, 2025 | $100.65 |
| 4 days before | 18.07% |
| 4 days after | -1.12% |
| On release day | -1.16% |
| Change in period | 16.75% |
| Release date | Mar 16, 2026 |
| Price on release | $93.05 |
| EPS estimate | $2.31 |
| EPS actual | $2.62 |
| EPS surprise | 13.42% |
| Date | Price |
|---|---|
| Mar 10, 2026 | $90.52 |
| Mar 11, 2026 | $91.60 |
| Mar 12, 2026 | $91.54 |
| Mar 13, 2026 | $91.91 |
| Mar 16, 2026 | $93.05 |
| Mar 17, 2026 | $94.58 |
| Mar 18, 2026 | $96.40 |
| Mar 19, 2026 | $97.16 |
| Mar 20, 2026 | $96.74 |
| 4 days before | 2.79% |
| 4 days after | 3.97% |
| On release day | 1.64% |
| Change in period | 6.87% |
| Release date | Jun 01, 2026 |
| Price on release | $115.08 |
| EPS estimate | $2.28 |
| EPS actual | $3.23 |
| EPS surprise | 41.67% |
| Date | Price |
|---|---|
| May 26, 2026 | $101.36 |
| May 27, 2026 | $101.66 |
| May 28, 2026 | $103.70 |
| May 29, 2026 | $104.20 |
| Jun 01, 2026 | $115.08 |
| Jun 02, 2026 | $113.36 |
| Jun 03, 2026 | $114.73 |
| Jun 04, 2026 | $116.57 |
| Jun 05, 2026 | $114.35 |
| 4 days before | 13.54% |
| 4 days after | -0.634% |
| On release day | -1.49% |
| Change in period | 12.82% |
SCIENCE APPLICATIONS INTERNATIONAL Earnings Call Transcript Summary of Q2 2026
SAIC reported mixed Q2 FY2026 results: revenue declined 2.7% year-over-year, driven by weaker on-contract growth, program disruptions and slower-than-expected new-award ramps. Adjusted EBITDA was $185 million (10.5% margin) with underlying margin improvement quarter-over-quarter. Book-to-bill remains healthy (>1.0; YTD 1.4) and backlog/pipeline stay strong (~$20B pending awards). Management lowered FY2026 revenue guidance to $7.25B–$7.325B (organic contraction ~2%–3%) and provided FY2027 revenue guidance of 0%–3%, citing continued near-term market volatility. They expect to mitigate revenue pressure through cost-efficiency actions (including accelerated AI adoption and an enterprise operating model) and are confident in margin expansion despite the weaker top line. Free cash flow outlook improved: FY2026 FCF > $550M and management expects multi-year cash tax benefits (~$200M total) related to Section 174 changes. Capital allocation remains shareholder-friendly (continued buybacks and M&A capacity) while keeping leverage discipline (~3x net debt/EBITDA target). Key risks are funding uncertainty, government acquisition delays, protests and program-specific disruptions; upside would come from normalization of on-contract growth, faster new-award ramps, and conversion of backlog into revenue.
